Table of contents
In this issue
p481 | doi:10.1038/nrd861
Editorial: A return to patent good sense
p483 | doi:10.1038/nrd868
Research Highlights
Amyloid diseases: A therapeutic knockout of SAP
p485 | doi:10.1038/nrd866
Metabolic diseases: Giving nature a helping hand
p486 | doi:10.1038/nrd847
Anti-inflammatories: Fishing for COX inhibitors
p486 | doi:10.1038/nrd848
Immune regulation: Place your T-BET on Crohn's disease
p487 | doi:10.1038/nrd849
G-Protein-coupled receptors: Easing the path to the surface
p488 | doi:10.1038/nrd854
Microbial diseases: Squatters' rights need ironing out
p488 | doi:10.1038/nrd863
Structure-based drug design: X-rated
p489 | doi:10.1038/nrd853
In brief
Ligand-gated ion channels | High-throughput screening | Antipyretics | Rational drug design
p489 | doi:10.1038/nrd862
Neurodegenerative diseases: TAU goes wild in Drosophila
p490 | doi:10.1038/nrd855
News and Analysis
Patent watch
Supreme Court rules on Festo
p490 | doi:10.1038/nrd867
From the analyst's couch
Market indicators
p491 | doi:10.1038/nrd842
Reviews
Article series: Case Histories
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Renaud Capdeville, Elisabeth Buchdunger, Juerg Zimmermann & Alex Matter
p493 | doi:10.1038/nrd839
Nucleic-acid therapeutics: basic principles and recent applications
Joanna B. Opalinska & Alan M. Gewirtz
p503 | doi:10.1038/nrd837
Optical biosensors in drug discovery
Matthew A. Cooper
p515 | doi:10.1038/nrd838
New horizons — alternative routes for insulin therapy
David R. Owens
p529 | doi:10.1038/nrd836
Genome-based pharmacogenetics and the pharmaceutical industry
Allen D. Roses
p541 | doi:10.1038/nrd840
Perspective
Innovation
Virtual screening using grid computing: the screensaver project
W. Graham Richards
p551 | doi:10.1038/nrd841
Top of page
Careers and Recruitment
Goal-driven drug discovery: getting the chemistry right
Nigel Shankley
p559 | doi:10.1038/nrd865
